Özlem Türeci, BioNTech co-founder and Uğur Şahin, BioNTech CEO

Third dose bumps up ef­fi­ca­cy of Pfiz­er-BioN­Tech's Covid-19 vac­cine in youngest group of chil­dren to 80%

Pfiz­er and BioN­Tech said Mon­day that they’re ready to ap­proach the FDA this week with ear­ly da­ta for their boost­er shot for Covid-19 vac­cine in the youngest age group (6 months to un­der 5 years), which showed 80.3% ef­fi­ca­cy based on 10 symp­to­matic Covid cas­es iden­ti­fied be­gin­ning sev­en days af­ter the third dose.

“The study sug­gests that a low 3-ug dose of our vac­cine, care­ful­ly se­lect­ed based on tol­er­a­bil­i­ty da­ta, pro­vides young chil­dren with a high lev­el of pro­tec­tion against the re­cent COVID-19 strains,” Uğur Şahin, CEO and co-founder of BioN­Tech said in a state­ment. “We are prepar­ing the rel­e­vant doc­u­ments and ex­pect com­plet­ing the sub­mis­sion process to the FDA this week, with sub­mis­sions to EMA and oth­er reg­u­la­to­ry agen­cies to fol­low with­in the com­ing weeks.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.